| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Comparative efficacy and safety of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomised trials
|
Khouri, Charles
|
|
|
1 |
4 |
p. e237-e246
|
article
|
| 2 |
Complications and adverse events of unicompartmental versus total knee replacement
|
Sayers, Adrian
|
|
|
1 |
4 |
p. e199-e200
|
article
|
| 3 |
Correction to Lancet Rheumatol 2019; 1: e229–36
|
|
|
|
1 |
4 |
p. e205
|
article
|
| 4 |
Correction to Lancet Rheumatol 2019; 1: e76–77
|
|
|
|
1 |
4 |
p. e205
|
article
|
| 5 |
Correction to Lancet Rheumatol 2019; 1: e23–34
|
|
|
|
1 |
4 |
p. e205
|
article
|
| 6 |
Disease heterogeneity in antineutrophil cytoplasmic antibody-associated vasculitis: implications for therapeutic approaches
|
Ford, Julia A
|
|
|
1 |
4 |
p. e247-e256
|
article
|
| 7 |
For lupus trials, the answer might depend on the question
|
Merrill, Joan T
|
|
|
1 |
4 |
p. e196-e197
|
article
|
| 8 |
Low-dose IL-2 for patients with systemic lupus erythematosus
|
He, Jing
|
|
|
1 |
4 |
p. e203
|
article
|
| 9 |
Low-dose IL-2 for patients with systemic lupus erythematosus – Authors' reply
|
Humrich, Jens Y
|
|
|
1 |
4 |
p. e203-e204
|
article
|
| 10 |
Medical cannabis: bridging the evidence gap
|
The Lancet Rheumatology,
|
|
|
1 |
4 |
p. e195
|
article
|
| 11 |
Misconceptions of arthritis and age: shake me, I rattle
|
Harding, Emilia
|
|
|
1 |
4 |
p. e207
|
article
|
| 12 |
Opioid use, postoperative complications, and implant survival after unicompartmental versus total knee replacement: a population-based network study
|
Burn, Edward
|
|
|
1 |
4 |
p. e229-e236
|
article
|
| 13 |
Raynaud's phenomenon: no net effects of vasodilators in a network analysis
|
Jaeger, Veronika K
|
|
|
1 |
4 |
p. e200-e202
|
article
|
| 14 |
Repurposing antidiabetic medications for gout: the potential of sodium glucose co-transporter 2 inhibitors
|
Neogi, Tuhina
|
|
|
1 |
4 |
p. e197-e199
|
article
|
| 15 |
Research in Brief
|
Thorley, Jennifer
|
|
|
1 |
4 |
p. e206
|
article
|
| 16 |
The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program
|
Li, JingWei
|
|
|
1 |
4 |
p. e220-e228
|
article
|
| 17 |
The nosology of systemic sclerosis: how lessons from the past offer new challenges in reframing an idiopathic rheumatological disorder
|
Lescoat, Alain
|
|
|
1 |
4 |
p. e257-e264
|
article
|
| 18 |
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
|
Furie, Richard A
|
|
|
1 |
4 |
p. e208-e219
|
article
|
Journal description